Berinert Coverage for Acute Hereditary Angioedema Attacks
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy 1011-14 alerts
Get alerted when Policy 1011-14 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and notification requirements for Berinert for adult and pediatric members with hereditary angioedema. Coverage is limited to treatment of acute attacks and excludes combination use with other products indicated for acute hereditary angioedema attacks.
The annual review updated the examples of therapies used for acute hereditary angioedema attacks.
Berinert Coverage Criteria
Berinert Coverage Criteria
Berinert will be approved when ALL of the following criteria are met:
All Berinert coverage criteria
- Diagnosis of hereditary angioedema (HAE): The member has a diagnosis of hereditary angioedema (HAE).
- Treatment of acute HAE attacks: Berinert is used for the treatment of acute HAE attacks.
- No combination therapy: Berinert is not used in combination with other products indicated for acute HAE attacks, such as Ekterly, Firazyr, Kalbitor, or Ruconest.
Coverage of Berinert requires that it is not used in combination with another product indicated for treatment of acute hereditary angioedema attacks, including Ekterly, Firazyr, Kalbitor, or Ruconest.
Prophylactic use of Berinert is not covered because the safety and efficacy of Berinert for prophylactic therapy have not been established.
Authorization and Denial Considerations
Obtain prior authorization or notification for Berinert
Prior authorization or notification applies to Berinert. Approval requires a diagnosis of hereditary angioedema, treatment of an acute hereditary angioedema attack, and no concurrent use of another product indicated for acute hereditary angioedema attacks.
Avoid noncovered use and combination therapy
Coverage may be denied when Berinert is not being used to treat an acute hereditary angioedema attack or when it is used in combination with another product indicated for acute hereditary angioedema attacks.
- Combination products include Ekterly, Firazyr, Kalbitor, or Ruconest.
- Prophylactic use is not covered because the safety and efficacy of Berinert for prophylactic therapy have not been established.
Confirm a hereditary angioedema diagnosis
Coverage may be denied when the member does not have a diagnosis of hereditary angioedema (HAE). Document the HAE diagnosis when requesting Berinert approval.
Clinical Background
Berinert is a plasma-derived C1 esterase inhibitor indicated for treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adult and pediatric patients. Its safety and efficacy for prophylactic therapy have not been established.
Key Terms
Initial Berinert Approval
Initial Berinert Approval
Initial approval requires ALL of the following:
All initial approval criteria
- Diagnosis of hereditary angioedema (HAE): The member has a diagnosis of hereditary angioedema (HAE).
- Treatment of acute HAE attacks: Berinert is used for the treatment of acute HAE attacks.
- No combination therapy: Berinert is not used in combination with other products indicated for acute HAE attacks, including Ekterly, Firazyr, Kalbitor, or Ruconest.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.